Loading…

miR-195, miR-455-3p and miR-10a super() are implicated in acquired temozolomide resistance in glioblastoma multiforme cells

To identify microRNAs (miRNAs) specifically involved in the acquisition of temozolomide (TMZ) resistance in glioblastoma multiforme (GBM), we first established a resistant variant, U251R cells from TMZ-sensitive GBM cell line, U251MG. We then performed a comprehensive analysis of miRNA expressions i...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2010-10, Vol.296 (2), p.241-248
Main Authors: Ujifuku, Kenta, Mitsutake, Norisato, Takakura, Shu, Matsuse, Michiko, Saenko, Vladimir, Suzuki, Keiji, Hayashi, Kentaro, Matsuo, Takayuki, Kamada, Kensaku, Nagata, Izumi, Yamashita, Shunichi
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To identify microRNAs (miRNAs) specifically involved in the acquisition of temozolomide (TMZ) resistance in glioblastoma multiforme (GBM), we first established a resistant variant, U251R cells from TMZ-sensitive GBM cell line, U251MG. We then performed a comprehensive analysis of miRNA expressions in U251R and parental cells using miRNA microarrays. miR-195, miR-455-3p and miR-10a super(*) were the three most up-regulated miRNAs in the resistant cells. To investigate the functional role of these miRNAs in TMZ resistance, U251R cells were transfected with miRNA inhibitors consisting of DNA/LNA hybrid oligonucleotides. Suppression of miR-455-3p or miR-10a super(*) had no effect on cell growth, but showed modest cell killing effect in the presence of TMZ. On the other hand, knockdown of miR-195 alone displayed moderate cell killing effect, and combination with TMZ strongly enhanced the effect. In addition, using in silico analysis combined with cDNA microarray experiment, we present possible mRNA targets of these miRNAs. In conclusion, our findings suggest that those miRNAs may play a role in acquired TMZ resistance and could be a novel target for recurrent GBM treatment.
ISSN:0304-3835
DOI:10.1016/j.canlet.2010.04.013